GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

The British pharma giant plans to shell out ... despite existing approved products,” Luke Miels, chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways to build past the GLP-1 space.

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers could be prevented from developing with jabs.

Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare ...

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab ... s Nucala for CRSwNP treatment" was originally created and published by Pharmaceutical Technology, a ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...